FAKTOR-OPTIONSSCHEIN - AGIOS PHARMA Share Price

Certificat

DE000MG15FX6

Market Closed - Börse Stuttgart 01:28:49 29/06/2024 am IST
21.77 EUR -0.64% Intraday chart for FAKTOR-OPTIONSSCHEIN - AGIOS PHARMA
Current month+26.35%
1 month+99.91%
Date Price Change
28/24/28 21.77 -0.64%
27/24/27 21.91 -4.78%
26/24/26 23.01 -10.22%
25/24/25 25.63 +0.35%
24/24/24 25.54 +21.68%

Delayed Quote Börse Stuttgart

Last update June 29, 2024 at 01:28 am IST

More quotes

Static data

Product typeProduits Exotiques
Buy / SellCALL
Underlying AGIOS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN MG15FX
ISINDE000MG15FX6
Date issued 27/03/2024
Strike 29.08 $
Maturity Unlimited
Parity 0.6 : 1
Emission price 10
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 32.31
Lowest since issue 7.87
Spread 0.3
Spread %1.36%

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Sector
-
More about the company

Ratings for Agios Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Agios Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
43.12 USD
Average target price
52.83 USD
Spread / Average Target
+22.53%
Consensus